Company News

Caleres (CAL) Maintains $0.07 Quarterly Dividend With 3.0% Yield, Ex-Date March 26

Caleres (CAL) Maintains $0.07 Quarterly Dividend With 3.0% Yield, Ex-Date March 26

Caleres declares $0.07 quarterly dividend, unchanged from prior quarter, yielding 3.0% with March 26 ex-date.

CTRN Reports $0.88 Per Share Earnings; Revenue Tops Consensus Estimates

Citi Trends posts $0.88 per share GAAP loss versus $0.18 estimate, missing by 11.5% despite revenue topping consensus by 1.3%…

Atour Lifestyle Reports $0.33 Q4 EPS, Down 86.1% YoY, as Revenue Surges 33.8% to $2.79B

Atour Lifestyle's Q4 EPS of $0.33 missed the $3.22 estimate by 89.8% despite revenue matching consensus at $2.79B, up 33.8%…

TME Earnings Miss: Q4 EPS of $0.23 Falls 85.6% Short of Estimates as Revenue Plunges 83.4%

TME's Q4 adjusted EPS of $0.23 missed estimates by 85.6% as revenue plunged 83.4% year-over-year, though net income surged to…

Chicago Atlantic BDC (LIEN) Q4 2025 Earnings Preview: NII and Credit Quality in Focus March 19

Chicago Atlantic BDC reports Q4 2025 results March 19 before the open, with investors focused on net investment income trends…

HUYA Stock Plunges: Q4 Revenue Crashes 83.4% YoY to $248.6M, Misses EPS by 106.5%

HUYA posts adjusted loss of $0.01 per share, missing estimates by 106.5%, as Q4 revenue plunges 83% year-over-year to $248.6…

Monte Rosa (GLUE) Reports Wider Q4 Loss of $0.55/Share vs $0.34 Estimate, Revenue Misses

Monte Rosa posts Q4 loss of $0.55/share vs $0.34 estimate, revenue of $2.8M misses $5.3M consensus by 47%.

CDNL Earnings Preview: What to Watch as Cardinal Infrastructure Reports Q4 Results on March 18

Cardinal Infrastructure reports Q4 2025 on March 19 with no consensus yet available; analysts have sharply raised 2026 estimates in…

Coda Octopus (CODA) Beats Q1 Estimates with $0.08 EPS, Revenue Surges 28.6% YoY to $6.7M

Coda Octopus posts $0.08 EPS vs $0.06 estimate; Q1 revenue of $6.7M climbs 28.6% year-over-year, topping consensus by 7.6%.

Bicycle Therapeutics (BCYC) Q4 Revenue Soars 1194.5% YoY to $48M, Crushing Estimates by 578%

Bicycle Therapeutics narrows Q4 loss to $0.29/share vs $0.95 estimate; revenue of $48M crushes $7.1M consensus by 578%.